Wang Jue, Wang Si, Luan Yun, Zhang Wenhua, Sun Chao, Cheng Guanghui, Li Kailin, Xin Qian, Lin Zhaomin, Qi Tonggang, Kong Feng
Central Laboratory, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Key Laboratory for Kidney Regeneration of Shandong Province, The Second Hospital of Shandong University, Jinan, Shandong 250033, P.R. China.
Oncol Lett. 2017 Dec;14(6):8021-8027. doi: 10.3892/ol.2017.7231. Epub 2017 Oct 20.
Scaffold protein neural precursor cell expressed, developmentally downregulated 9 (NEDD9) is a member of the Crk-associated substrate protein family and is known to be a biomarker in multiple cancer types. It serves a critical function in regulating cell proliferation, migration, invasion and survival. The objective of this study was to evaluate the potential effects of NEDD9 in renal cell carcinoma (RCC). The expression of NEDD9 was analyzed by immunohistochemistry, western blotting and reverse transcription-quantitative polymerase chain reaction. NEDD9 protein and mRNA levels were significantly upregulated in RCC tissues compared with normal tissues (P<0.001). Furthermore, the NEDD9 immunostaining level was significantly associated with primary tumor stage and tumor, node, metastasis stage (P<0.05). High NEDD9 expression resulted in significantly lower survival rates for patients compared with normal NEDD9 expression (P<0.01). In addition, wound healing and transwell assays indicated that NEDD9 depletion by small interfering RNA significantly attenuated the migration and invasion of RCC cells (P<0.001). The present data suggested that NEDD9 may be a novel target for prevention and treatment of RCC metastasis and recurrence.
支架蛋白神经前体细胞表达、发育下调9(NEDD9)是Crk相关底物蛋白家族的成员,已知是多种癌症类型的生物标志物。它在调节细胞增殖、迁移、侵袭和存活中起关键作用。本研究的目的是评估NEDD9在肾细胞癌(RCC)中的潜在作用。通过免疫组织化学、蛋白质印迹法和逆转录-定量聚合酶链反应分析NEDD9的表达。与正常组织相比,RCC组织中NEDD9蛋白和mRNA水平显著上调(P<0.001)。此外,NEDD9免疫染色水平与原发肿瘤分期和肿瘤、淋巴结、转移分期显著相关(P<0.05)。与正常NEDD9表达相比,高NEDD9表达导致患者生存率显著降低(P<0.01)。此外,伤口愈合和Transwell实验表明,小干扰RNA介导的NEDD9缺失显著减弱了RCC细胞的迁移和侵袭(P<0.001)。本研究数据表明,NEDD9可能是预防和治疗RCC转移和复发的新靶点。